Association of changes in D-dimer and other coagulation markers with changes in Marder score after treatment of acute venous thrombosis

J Thromb Thrombolysis. 2002 Aug;14(1):73-8. doi: 10.1023/a:1022022523146.

Abstract

Aim: Coagulation markers are sensitive tools to assess ongoing thrombus formation. An association between changes in these markers and changes in venographic Marder scores in patients with acute deep vein-thrombosis treated with low-molecular-weight (LMWH) or unfractionated heparin (UFH) has not been reported.

Methods: We investigated differences in coagulation parameters before and at the end of a twelve days the treatment of patients with an improvement versus no improvement of the venographic findings at the end of the treatment with LMWH (n = 48) and UFH (n = 41).

Results: Patients with lower values in the Marder score had lower D-dimer levels at day 12 compared to entry treated with UFH and LMWH (p < 0.001). Not improved Marder scores paralleled unchanged D-dimer levels at end of both treatments. Higher values of factor-Xa inhibition and Heptest assay (p < 0.001) were measured at the end of treatment in LMWH- in contrast to UFH-patients. Thrombin inhibition was lower and unchanged at day 12 in patients treated with LMWH and UFH, respectively. Thrombin generation inhibition and release of tissue-factor pathway inhibitor remained unchanged in both groups.

Conclusion: An improved Marder score is associated with a decrease of D-dimer during UFH and LMWH treatment of deep vein-thrombosis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Anticoagulants / blood*
  • Anticoagulants / therapeutic use
  • Biomarkers / blood
  • Blood Coagulation Factors / metabolism
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Heparin, Low-Molecular-Weight / blood
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Statistics, Nonparametric
  • Venous Thrombosis / blood*
  • Venous Thrombosis / drug therapy

Substances

  • Anticoagulants
  • Biomarkers
  • Blood Coagulation Factors
  • Fibrin Fibrinogen Degradation Products
  • Heparin, Low-Molecular-Weight
  • fibrin fragment D